Ultragenyx Pharmaceutical Inc. (RARE) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-18

Business type: Asset play

How it makes money

It earns revenue by selling specialized biopharmaceutical therapies for rare genetic diseases, driven primarily by increasing demand for its approved products.

The company commercializes therapies targeting rare and ultra-rare genetic disorders, generating product revenues that reached $673 million for the year ended December 31, 2025, compared to $560 million for the same period in 2024. Profitability is heavily influenced by commercial adoption and higher demand across its approved portfolio, which includes treatments such as Crysvita, Mepsevii, Dojolvi, and Evkeeza.

What protects it: the moat

It protects its market position through patent rights, orphan drug exclusivities, and specialized rare disease execution, though third-party dependence remains a risk.

Management asserts that its competitive edge relies on proprietary rights, patent protection, and specialized expertise in clinical development for rare conditions. However, the company is dependent on external partners such as Kyowa Kirin Co., Ltd. for key products like Crysvita in major markets, and faces potential threats from biosimilars or generic competitors.

What growth costs

It incurs substantial costs primarily from ongoing research and development programs and selling, general, and administrative expenses, resulting in recurring net losses.

The company invests heavily in identifying, acquiring, and developing product candidates through clinical studies, alongside operating its commercial organization. For the years ended December 31, 2025 and 2024, it incurred net losses of $575 million and $569 million, respectively, driven largely by these research, development, and operational overhead costs.

What could damage it

A failure of single-source suppliers to provide necessary product supply could severely disrupt commercialization and impair financial results.

Because the company relies on third parties for manufacturing its products and product candidates, any failure by these single-source suppliers to deliver clinical or commercial supplies would halt sales and development programs, directly attacking its ability to generate revenue from approved therapies.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Other companies in Biotechnology